First-Line Gemcitabine Plus Cisplatin in Nonsmall Cell Lung Cancer Patients
Joint Authors
Lou, Yan
Li, Ying
Zhang, Guo Bing
Wang, Lin Run
Chen, Jian
Source
Issue
Vol. 2014, Issue 2014 (31 Dec. 2014), pp.1-9, 9 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2014-01-23
Country of Publication
Egypt
No. of Pages
9
Main Subjects
Abstract EN
Aim.
To evaluate the predictive value of RRM1, ERCCl, and BRCA1 expression in Chinese NSCLC patients treated with gemcitabine and cisplatin.
Methods.
Real-time fluorescent quantitative PCR was used to determine the RRM1, ERCC1, and BRCA1 mRNA expression levels of peripheral blood in late-stage NSCLC patients.
The relationship between peripheral blood and mRNA expression in tumor tissues was analyzed further.
Results.
In terms of the tumor susceptibility to chemotherapy, the response rate in the low-RRM1-expression group was significantly greater than in the high-expression group (52.9% versus 5.9%, χ2 test, P=0.007).
Subjects with low peripheral blood RRM1 expression survived longer than those with high RRM1 expression (15.5 versus 12.0 months, logrank 3.980, P=0.046).
Linear correlations were observed between peripheral blood and tumor tissue expression levels for RRM1 (R2=0.045, P=0.048) and BRCA1 (R2=0.021, P=0.001).
Conclusion.
Our study demonstrates increased survival and superior efficacy of gemcitabine and cisplatin combination chemotherapy in the treatment of NSCLC patients with low peripheral blood RRM1 expression.
The linear correlations of the relative expression of mRNA were observed between peripheral blood and tumor tissue expression levels for RRM1 and BRCA1.
RRM1 gene expression may contribute to chemotherapy sensitivity and may be an indicator of survival.
It was significant to individual chemotherapy of patients with advanced NSCLC who do not have sufficient tumor tissue.
American Psychological Association (APA)
Li, Ying& Wang, Lin Run& Chen, Jian& Lou, Yan& Zhang, Guo Bing. 2014. First-Line Gemcitabine Plus Cisplatin in Nonsmall Cell Lung Cancer Patients. Disease Markers،Vol. 2014, no. 2014, pp.1-9.
https://search.emarefa.net/detail/BIM-511590
Modern Language Association (MLA)
Li, Ying…[et al.]. First-Line Gemcitabine Plus Cisplatin in Nonsmall Cell Lung Cancer Patients. Disease Markers No. 2014 (2014), pp.1-9.
https://search.emarefa.net/detail/BIM-511590
American Medical Association (AMA)
Li, Ying& Wang, Lin Run& Chen, Jian& Lou, Yan& Zhang, Guo Bing. First-Line Gemcitabine Plus Cisplatin in Nonsmall Cell Lung Cancer Patients. Disease Markers. 2014. Vol. 2014, no. 2014, pp.1-9.
https://search.emarefa.net/detail/BIM-511590
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-511590